Altekuse SF, Kosary CL, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2007. NCI, Bethesda, 2010.
Grieb G, Merk M, Bernhagen J and Bucala R: Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect 23: 257-264, 2010.
Santos LL and Morand EF: Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 399: 1-7, 2009.
Conroy H, Mawhinney L and Donnelly SC: Inflammation and cancer: macrophage migration inhibitory factor (MIF) - the potential missing link. QJM 103: 831-836, 2010.
Mitchell RA: Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16: 13-19, 2004.
Rendon BE, Willer SS, Zundel W and Mitchell RA: Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol 3: 180-185, 2009.
Tarnowski M, Grymula K, Liu R, et al: Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol Cancer Res 8: 1328-1343, 2010.
Martinez LM, Vallone VB F, Labovsky V, et al: Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases. Clin Exp Metastasis 31: 213-232, 2014.
Lue H, Thiele M, Franz J, et al: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the AKT pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26: 5046-5059, 2007. (Pubitemid 47206949)
Bernhagen J, Krohn R, Lue H, et al: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587-596, 2007. (Pubitemid 46828480)
Zernecke A, Bernhagen J and Weber C: Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117: 1594-1602, 2008. (Pubitemid 351440647)
Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J and Bucala R: Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 99: 345-350, 2002. (Pubitemid 34060365)
Fersching DMI, Nagel D, Siegele B, Salat C, Heinemann V, Holdenrieder S and Stoetzer OJ: Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy. Anticancer Res 32: 2047-2058, 2012.
Verjans E, Noetzel E, Bektas N, et al: Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 9: 230, 2009.
Bando H, Matsumoto G, Bando M, et al: Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jnp J Cancer Res 93: 389-396, 2002. (Pubitemid 34506248)
Xu X, Wang B, Ye C, et al: Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 261: 147-157, 2008. (Pubitemid 351253721)
Tian B, Zhang Y, Li N, Liu X and Dong J: CD74: a potential novel target for triple-negative breast cancer. Tumour Biol 33: 2273-2277, 2012.
Greenwood C, Metodieva G, Al-Janabi K, et al: Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteomics 75: 3031-3040, 2012.
Metodieva G, Correa Nogueira-de-Souza N, Greenwood C, Al-Janabi K, Leng L, Bucala R and Metodiev MV: CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. Neoplasia 15: 660-668, 2013.
Schulz R, Marchenko ND, Holemboswki, et al: Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med 209: 275-289, 2012.
Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV and Goldenberg DM: Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 12: 968-978, 2013.
Hammond EH, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134: 48-72, 2010.
Dowset M, Nielsen TO, A'Hern R, et al: Assesment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 103: 1656-1664, 2011.
Schrohl AS, Pedersen HC, Jensen SS, Nielsen S and Brünner N: Human epidermal growth factor receptor (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 59: 975-983, 2011.
Preat F, Simon P and Noel JC: Differences in breast carcinoma immunohistochemical subtypes between immigrant Arab and European women. Diagn Pathol 9: 26, 2014.
Cludts S, Decaestecker Ch, Johnson B, et al : Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res 30: 3313-3319, 2010.
Kindt N, Lechien J, Decaestecker C, et al. Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res 32: 4499-4505, 2012.
Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lorkshin AE and Lo JY: Do serum biomarkers really measure breast cancer? BMC Cancer 9: 164, 2009.
Simpson KD, Templeton DJ and Cross JV: Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 189: 5533-5540, 2012.
Kim H, Lee S, Kim JH, et al: Elevated levels of macrophage migration inhibitory factor in women with metabolic syndrome. Horm Metab Res 43: 642-645, 2011.
Kolar M, Szabo P, Dvorankova B, et al: Upregulation of IL-6, IL-8 and CXCL-1 production in dermal fibroblasts by normal/malignant epithelial cells in vitro: Immunohistochemical and transcriptomic analyses. Bio Cell 104: 738-751, 2012.
Catteau X, Simon P, Vanhaeverbeek M and Noël JC: Variable stromal periductal expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast. PLoS One 8: e5773, 2013.
Meyer-Siegler KL, Iczkowski KA and Vera PL: Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 5: 73, 2005.
McClelland M, Zhao L, Carskadon S and Arenberg D: Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol 174: 638-646, 2009.
von Minckwitz G, Eidtmann H, Rezai M, et al: Neoadjuvant chemotherapy and bevacizumab for HER-2 negative breast cancer. N Engl J Med 366: 299-309, 2012.
Zhang L, Ye SB, Ma G, et al: The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma. J Transl Med 11: 60, 2013.
Du W, Wright BM, Li X, et al: Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma. Oncogene 32: 1469-1474, 2013.
